In the increasingly competitive digital health space, startups and established technology players are discovering that partnership—not isolated development—is the fastest path to meaningful clinical innovation. A recent example comes from ProVoyance™ and intive, who have formalized a collaboration under the name “ProVoyance™ powered by intive.”
Rather than treating the orthopedic device market as a static industry, the two companies see it as a sector ripe for modernization. With an estimated value of $60–63 billion in 2024, and projections surpassing $80 billion by 2032, the need for more efficient and predictable workflows is pushing providers to adopt intelligent digital tools.
The strength of the partnership lies in how the companies complement each other. ProVoyance™ specializes in helping medical device manufacturers adopt data-driven processes. intive brings large-scale engineering capabilities and experience building regulated digital platforms.
Together, they aim to modernize orthopedic care by integrating AI into imaging, diagnostics, and surgical planning.
Claudio González, CTO & EVP at intive, describes the mission: “We’re bridging the gap between traditional medical device manufacturing and healthcare’s digital future.”
Turning collaboration into clinical value
Their joint roadmap includes SaMD development, AI-enhanced features for medical devices, and new visualization tools designed to reduce surgical variability. But beyond individual products, the companies believe the partnership itself is what enables long-term innovation.
“This partnership uniquely positions us to transform clinical processes and create new opportunities. The resulting solutions enable healthcare providers to optimize time, reduce costs, and most importantly, improve patient outcomes”, said Matt Miller, Head of Technology Development at ProVoyance™.
For the broader startup ecosystem, the ProVoyance™–intive collaboration shows how alliances can help bridge gaps between regulation, engineering, and clinical adoption—gaps that often slow innovation.
In a sector where precision and reliability define success, the partnership illustrates how combined expertise can accelerate the path from concept to clinical use.
